BC
LGND icon

Burney Company’s Ligand Pharmaceuticals LGND Stock Holding History

Burney Company’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,861
Closed -$1.56M – 592
2025
Q1 		$1.56M Buy
14,861
+1,341
+10% +$152K 0.06% 247
2024
Q4 		$1.45M Buy
13,520
+2,399
+22% +$271K 0.05% 262
2024
Q3 		$1.11M Buy
11,121
+7,650
+220% +$770K 0.04% 300
2024
Q2 		$292K Sell
3,471
-53
-2% -$4.22K 0.01% 516
2024
Q1 		$258K Buy
3,524
+416
+13% +$30.7K 0.01% 546
2023
Q4 		$222K Buy
+3,108
New +$183K 0.01% 543
2023
Q3 		– Sell
-52,030
Closed -$3.75M – 583
2023
Q2 		$3.75M Buy
+52,030
New +$3.9M 0.17% 156

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Burney Company's LGND Position: Q2 2025 in Review

Burney Company sold out of Ligand Pharmaceuticals (LGND) in Q2 2025, closing a stake of 14,861 shares — an estimated $1.56M sold.

Burney Company first reported a position in LGND in Q2 2023 and held it in 7 quarters. The position peaked at $3.75M in Q2 2023. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

  • Burney Company reported no remaining Ligand Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Burney Company sold 14,861 Ligand Pharmaceuticals shares in Q2 2025, an estimated $1.56M.
  • Burney Company first reported a position in Ligand Pharmaceuticals in Q2 2023 and held it in 7 quarters.
  • Burney Company's Ligand Pharmaceuticals position peaked at $3.75M in Q2 2023.
  • 271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on Burney Company's 13F filing for Q2 2025, filed 5 Aug 2025.